Navigation Links
Vasogen Announces 2008 Year-End Results
Date:2/27/2009

MISSISSAUGA, ON, Feb. 27 /PRNewswire-FirstCall/ - Vasogen Inc. (NASDAQ: VSGN; TSX:VAS) today reported the results of operations for the fiscal year ended November 30, 2008. All dollar amounts referenced herein are in Canadian dollars unless otherwise noted.

At November 30, 2008, our cash and cash equivalents totaled $8.6 million, compared with $23.5 million at November 30, 2007 and $9.8 million at August 31, 2008. As of January 31, 2009, our cash balance was $8.5 million.

The net loss for the fourth quarter of 2008 was $0.8 million, or $0.03 per common share. We incurred a net loss for the year ended November 30, 2008 of $16.1 million, or $0.72 per common share, compared with a net loss of $28.8 million, or $1.46 per common share for the same period in 2007. A key driver of this decrease was lower compensation costs, reduced stock compensation expense, lower infrastructure and other support costs driven by lower employee numbers in 2008, and a decrease in the foreign exchange loss that was incurred in the prior period. In addition, the decrease was impacted by a reduction in expenses resulting from the repayment of the senior convertible notes in April 2007.

    Corporate Update

    -   During 2008, we implemented our restructuring plan to significantly
        reduce the rate at which we use our cash and to focus our efforts on
        opportunities that the Board and Management believe are most likely
        to provide shareholder value. As a result, we discontinued
        maintaining the necessary quality processes and personnel to support
        European commercialization and any clinical development of our
        Celacade technology, materially reduced expenses associated with the
        VP series of drugs, and reduced the number of full-time employees
        from 104 to six. We also retained JMP Securities 
'/>"/>
SOURCE  Vasogen Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 

Related biology technology :

1. Vasogen Announces Sale of Patent Application and Provides Corporate Update
2. Vasogen Complies with NASDAQ Marketplace Rule 4350(c)(1)
3. Vasogen Provides Corporate Update
4. Vasogen Announces Third Quarter 2008 Results
5. Vasogen Announces Second Quarter 2008 Results
6. Vasogen Provides Corporate Update
7. Vasogen to Webcast Presentation at the Rodman & Renshaw 5th Annual Global Healthcare Conference
8. Vasogen Receives NASDAQ Notification Related to Minimum Bid Price
9. Vasogen Announces Implementation of Strategic Restructuring Plan
10. Vasogen Announces First Quarter 2008 Results
11. Vasogen to Webcast its Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... and NEW ORLEANS , May 22, ... field of regenerative medicine, presented new data generated in ... Group (a leading health economics consultancy) demonstrating the significant ... (DFU) and venous leg ulcers (VLU) place upon the ... this research, which reveal annual costs of up to ...
(Date:5/22/2013)... Express Diagnostics Int’l, Inc. (EDI) , ... pleased to announce a sponsorship agreement with Erebus Motorsport ... distributor of DrugCheck® onsite testing devices, manufactured by EDI. ... Austin 400 May 17-19 in Austin, Texas. , Royal ... each car of the Erebus Motorsport team displaying the ...
(Date:5/22/2013)... -- Moderna Therapeutics, the pioneering company developing messenger RNA therapeutics™, ... in vivo production of therapeutic proteins, announced today ... Moderna in early July as its first Chief Information ... in the design and implementation of information systems underlying ... clinical operations and commercial preparedness. John has also been ...
(Date:5/21/2013)... WA (PRWEB) May 21, 2013 Through ... trainings, and funds for lab equipment, 25 organizations will ... and importance of optics and photonics in daily life ... . , The organizations, located in 10 countries, are ... to be awarded by SPIE, the international society ...
Breaking Biology Technology:Organogenesis Presents Findings from Groundbreaking Research Highlighting the Healthcare Resource and Economic Burden of Venous Leg Ulcers and Diabetic Foot Ulcers 2Organogenesis Presents Findings from Groundbreaking Research Highlighting the Healthcare Resource and Economic Burden of Venous Leg Ulcers and Diabetic Foot Ulcers 3Organogenesis Presents Findings from Groundbreaking Research Highlighting the Healthcare Resource and Economic Burden of Venous Leg Ulcers and Diabetic Foot Ulcers 4Australian Distributor of Express Diagnostics Signs Sponsorship Agreement with V8 Supercar Team 2Industry Leader John Reynders Joins Moderna Therapeutics as Chief Information Officer 2Industry Leader John Reynders Joins Moderna Therapeutics as Chief Information Officer 3Learning About Light: Education Outreach Projects Funded in 10 Countries Through First Round of SPIE Grants 2Learning About Light: Education Outreach Projects Funded in 10 Countries Through First Round of SPIE Grants 3
... Partners B.V., a leading,GMP biopharmaceutical manufacturer, announced today ... ActoGeniX, drug substance AG011 for use in a,Phase ... ActoGeniX is focused on the development and commercialization ... can,be orally administered. The Company,s lead product AG011 ...
... JERSEY CITY, New Jersey, May 14, Rosetta Genomics (Nasdaq: ... financial results on May 21, 2008, before the,U.S. markets ... a,simultaneous webcast to discuss these results at 4:30 p.m. ... conference call, U.S. and Canadian participants may,dial +1-866-966-5335; international ...
... May 14 Access Pharmaceuticals, Inc.,(OTC Bulletin Board: ACCP) ... Rodman & Renshaw 5th Annual Global Healthcare Conference to ... Hotel in Monte Carlo, Monaco.,Jeffrey B. Davis, CEO of ... at 3:10 pm local time, 9:10 am Eastern time ...
Cached Biology Technology:SynCo Bio Partners Completes Manufacture and Release of ActoGeniX' Lead Product for Phase II Clinical Trials 2SynCo Bio Partners Completes Manufacture and Release of ActoGeniX' Lead Product for Phase II Clinical Trials 3Rosetta Genomics Announces Conference Call and Webcast of First Quarter Financial Results 2Access Pharmaceuticals to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference 2
(Date:5/21/2013)... A new analysis shows that the nation,s land ... enough algae to produce up to 25 billion gallons ... one-twelfth of the country,s yearly needs. , The findings ... that would be needed to grow significant amounts of ... were published in the May 7 issue of ...
(Date:5/21/2013)... Researchers at USC have found that a class of ... mice. , The drugs, known as "TSPO ligands," ... "We looked at the effects of TSPO ligand in ... stage, and in aged mice when pathology was quite ... Davis School of Gerontology. "TSPO ligand reduced measures of ...
(Date:5/21/2013)... Cancers of all types become most deadly when they ... has reached this stage, it becomes very difficult for ... can develop. Now, researchers at the University of Missouri ... target lymphoma tumor cells wherever they may be in ... in the MU College of Veterinary Medicine, says being ...
Breaking Biology News(10 mins):Going green: Nation equipped to grow serious amounts of pond scum for fuel 2Going green: Nation equipped to grow serious amounts of pond scum for fuel 3Going green: Nation equipped to grow serious amounts of pond scum for fuel 4Drugs found to both prevent and treat Alzheimer's disease in mice 2MU researchers develop radioactive nanoparticles that target cancer cells 2
... French . MONTREAL, March 1, 2011 ... rare genetic disease, researchers have discovered how three genes contribute ... understanding of many disorders such as foetal and childhood growth ... result of the Human Genome Project, we know the basic ...
... Cambridge, MASS- When your brain encounters sensory stimuli, such as ... a honking car, that input gets shuttled to the appropriate ... olfactory cortex, while sounds are processed in the auditory cortex. ... follows a predetermined, genetic blueprint. However, evidence is mounting that ...
... Canuel of the Virginia Institute of Marine Science ... Canada, and Mexico who have been awarded a ... As a Leopold Fellow, Canuel will participate in ... Capitol Hilldesigned to promote effective communication of science ...
Cached Biology News:Researchers looking at a rare disease make breakthrough that could benefit everyone 2Researchers looking at a rare disease make breakthrough that could benefit everyone 3MIT-- parts of brain can switch functions 2MIT-- parts of brain can switch functions 3MIT-- parts of brain can switch functions 4VIMS professor selected as Leopold Fellow 2VIMS professor selected as Leopold Fellow 3
... EPS 301 Power Supply, 1. ... maximum.Constant voltage or constant current modes.Single-unit ... precision and reproducibility.Suitable for submarine, mini ... as well as semidry and mini ...
... Supply, 1. 1000 V, 400 mA, ... and constant power modes.Single-unit increments in ... reproducibility.Stores and recalls three protocols.Outstanding choice ... Multiphor II or GenePhor systems. ...
Mouse TrkC Affinity Purified Polyclonal Ab...
Immunogen: Full length M32 fusion protein. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Biology Products: